Masimo’s revolutionary SET® pulse oximetry has been shown in more than 100 independent and objective studies to outperform other pulse oximetry technologies – even before the revisions that achieved ...

IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) today announced the findings of an abstract presented last Saturday at the Society for Technology in Anesthesia 2022 Annual Meeting, which ...

NICU Study Adds to the Evidence Demonstrating SET®’s Accuracy in Challenging Real-World Settings, With No Clinically Significant Differences in Performance Across Skin Pigmentation Categories or Race ...

NEUCHATEL, Switzerland--(BUSINESS WIRE)-- Masimo (NASDAQ: MASI) today announced the CE marking of the Rad-G™ with Temperature, a rugged handheld device that provides clinically proven SET® pulse ...

Stateside, the ORi sensor will be available in several of Masimo’s RD Rainbow pulse oximetry devices: a newly launched one that features four LED sensors and can calculate both oxygen saturation and ...

The FDA clearance allows the W1 wearable to be sold for both over-the-counter and prescription use—making it the first SpO2-tracking smartwatch to carry both indications in the U.S., per Masimo.

These promising results-from an NIH-funded study that exclusively evaluated Masimo SET ® in a vulnerable, clinically fragile patient population-add to previously published evidence of its strong ...

These promising results—from an NIH-funded study that exclusively evaluated Masimo SET ® in a vulnerable, clinically fragile patient population—add to previously published evidence of its strong ...